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Abstract In thrombin-stimulated platelets (XiibP3 integrin en-
gagement triggers both phosphatidylinositol 3',4'-6wphosphate 
synthesis and calpain activation. We checked the possible 
involvement of calpains in phosphatidylinositol 3-kinase signal-
ling pathway using a cell permeant specific inhibitor of calpains, 
calpeptin. In conditions where thrombin-induced platelet aggre-
gation and secretion were not impaired, we found a dose-
dependent inhibition of phosphatidylinositol 3,4-6wphosphate 
synthesis by calpeptin from 50 jig/ml. Moreover, pretreatment 
of platelets by both calpeptin and the peptide RGDS, an inhibitor 
of fibrinogen binding to activated anbp3 integrin, did not induce 
additive effects on phosphatidylinositol 3,4-/>/vphosphate inhibi-
tion. Finally, the p85 regulatory subunit of phosphatidylinositol 
3-kinase was still translocated to the cytoskeleton in calpeptin-
treated platelets. These data indicate that calpains are involved in 
the regulation of a1Ibp3 integrin-dependent phosphatidylinositol 
3-kinase signalling pathway. 
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1. Introduction 
Calpams are Ca2+-dependent cytoplasmic cysteine proteases 
that are widely distributed in mammalian cells [1]. In stimu-
lated platelets, translocation to the membrane cytoskeleton 
and activation of calpains are detected by 10 and 30 s after 
thrombin addition, respectively [2]. Activation but not redis-
tribution of calpains requires ccubPs integrin engagement and 
platelet aggregation [2]. Upon platelet activation, am,P3 integ-
rin has been shown to promote calcium influx [3], a determin-
ing factor of calpain activation [4]. The isoforms m- and u-
calpain require 300-500 and 10-100 uM Ca2+ for in vitro 
activity, respectively. Activation of calpains results in selective 
hydrolysis of several platelet proteins including cytoskeletal 
proteins, i.e. actin-binding protein (ABP), talin, spectrin, 
calmodulin-binding proteins and signalling enzymes, i.e. phos-
pholipase Cp3 [5], protein kinase C [6], tyrosine kinase 
pp60c~src [7], tyrosine phosphatase PTP-1B [8]. Moreover, a 
calpain-dependent hydrolysis of the cytoplasmic domain of P3 
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integrin has been recently described in thrombin-stimulated 
platelets [9]. Calpains have been involved in the shedding of 
procoagulant membrane vesicles and bloating of filopod sur-
faces in stimulated platelets [10,11], two processes which are 
closely related to intracellular cytoskeletal reorganization. 
Thrombin activation of platelets triggers synthesis of the 
Ptdlns 3-kinase products, PtdIns(3,4,5)P3 and PtdIns(3,4)P2, 
which seems to be necessary for irreversible aggregation to 
occur [12]. PtdIns(3,4,5)P3 reaches its peak value within 20 s 
of stimulation in a Ca2+- and ocmA-! integrin-independent 
manner [13]. On the other hand, PtdIns(3,4)P2 is only detect-
able 30 s after thrombin addition with a rapid phase before 90 
s that is independent of fibrinogen/anbPs integrin interaction 
and Ca2+, followed by a late phase that is associated with 
ocnbP:j integrin engagement and Ca2+ [13]. Two isoforms of 
Ptdlns 3-kinase, heterodimeric p85/pll0 and monomeric 
pllOy, have been shown in platelets. In thrombin-stimulated 
platelets, we have previously shown that anbP3 integrin regu-
lates the translocation of the regulatory subunit p85 to the 
cytoskeleton, which is closely related to <XnbP3 integrin-de-
pendent PtdIns(3,4)P2 synthesis [14]. Moreover, the redistrib-
ution of p85 allows its interaction with pl25F A K tyrosine kin-
ase and subsequently leads to Ptdlns 3-kinase activation [14]. 
Because calpains and Ptdlns 3-kinase are both localized in 
focal adhesion sites, regulated by ocubPs integrin engagement, 
and involved in cytoskeleton reorganization, we have consid-
ered the possibility that the two signal transduction systems 
may interact during platelet activation. 
In order to check the possible involvement of calpains in 
PtdIns(3,4)P2 production by thrombin-stimulated platelets, we 
used the cell permeant specific inhibitor of calpains, calpeptin 
[15]. This study shows that pretreatment of platelets with cal-
peptin inhibits that part of PtdIns(3,4)P2 synthesis which is 
dependent on oinbP3 integrin engagement upon thrombin stim-
ulation without impairment of p85 translocation to the cyto-
skeleton. 
2. Materials and methods 
2.1. Preparation of platelets 
Human platelets were isolated by centrifugation from fresh platelet 
concentrates (Etablissement de Transfusion Sanguine Pyrenees-Gar-
onne, Toulouse, France) and labelled for 90 min with 0.4 mCi/ml 
[y-32P]phosphate (Amsterdam, Ltd., Buckinghamshire, UK) as previ-
ously described [16]. Platelets were finally resuspended in modified 
Tyrode's buffer (pH 7.4) containing 2.5 mM CaCl2. 
2.2. Calpeptin incorporation and platelet activation 
Calpeptin was purchased from Novabiochem (France Biochem, 
Meudon, France). Calpeptin (25-75 ug/ml) in DMSO or DMSO alone 
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was added to platelets for 5 min at 37°C under shaking before stim-
ulation by thrombin. The final amount of DMSO was maximally 
0.3% of the total volume. Thrombin activation of the platelets was 
obtained by adding 1 NIH unit of human thrombin (Sigma, St. Louis, 
MO, USA) per ml of suspension (3 X 108 platelets/ml). Incubation was 
carried on for 5 min under shaking. In some experiments, the syn-
thetic peptide RGDS (Sigma) was added 15 s before thrombin. 
Platelet release reaction was checked by [14C]serotonin appearance 
in the supernatants after 1 min of thrombin stimulation. Aggregation 
was checked by turbidimetry. 
2.3. Lipid extraction and analysis 
Lipid extraction, which served also to quench the reactions, was a 
modified procedure of Bligh and Dyer [16]. Lipids were then deacy-
lated by methylamine treatment, and separated by HPLC on a Parti-
sphere SAX column (Whatman International Ltd., UK) using an 
elution gradient of 0-1 M ammonium phosphate as previously de-
scribed [16]. Radioactivity was detected on line with a Berthold 
LB506C radioactivity monitor. 
2.4. Cytoskeleton extraction and immunodetection of p85 
Cytoskeleton extraction was obtained in the presence of 1% Triton 
X-100, which also made it possible to stop the reactions as described 
previously [17]. Cytoskeleton separated from Triton X-100-soluble 
fractions by centrifugation was then washed twice with Tris buffer 
containing 0.5 and 0% Triton X-100 [17]. Finally, cytoskeleton was 
resuspended in Tris 20 mM pH 7.4 by sonication (20 kHz for 2x10 s) 
using an ultrasonic cell disrupter. Proteins were solubilized, separated 
on 5-15% SDS-PAGE, and blotted onto nitrocellulose as described 
previously [14]. After nitrocellulose blockade, immunodetection of p85 
was performed with a rat anti-p85 antibody from Upstate Biotechnol-
ogy Inc. (New York). Antibody reaction was visualized using alkaline 
phosphatase-conjugated secondary antibodies. 
3. Results 
3.1. Calpeptin inhibition of PtdIns(3,4)Pi synthesis in 
thrombin-stimulated platelets 
Calpeptin has been largely used as a cell permeant specific 
inhibitor of calpains in platelets at concentrations between 10 
and 200 ug/ml [5,8,11]. Since PtdIns(3,4)P2 synthesis is de-
pendent on aggregation triggered by thrombin stimulation 
of platelets, we first checked the effects on platelet aggregation 
and secretion of pretreatment by calpeptin. As shown in Fig. 
1, up to 75 |xg/ml of calpeptin did not significantly affect 
platelet aggregation and secretion. The extent of platelet ag-
gregation was reduced at 100 Ug/ml of calpeptin with forma-
tion of small platelet aggregates but no reversible aggregation 
(Fig. 1). In conditions where platelet aggregation and secre-
tion induced by thrombin were not affected, calpeptin treat-
ment provoked a dose-dependent inhibition of [32P]-
PtdIns(3,4)P2 already significant at 50 ug/ml (Fig. 2). With 
regard to preservation of platelet aggregation, maximal inhib-
ition of [32P]PtdIns(3,4)P2 level was obtained at 75 ug/ml of 
calpeptin (—60% on average). These data suggest that calpains 
are involved in platelet PtdIns(3,4)P2 synthesis upon thrombin 
stimulation. 
3.2. PtdIns(3,4)P-i synthesis inhibited by calpeptin is secondary 
to OtnbPs engagement 
We have previously shown that otubPs integrin engagement 
was responsible for 63% ±17 (mean ± S.D.) of the platelet 
PtdIns(3,4)P2 synthesis upon thrombin stimulation [18]. We 
checked whether the inhibitory effect of calpeptin treatment 
concerned the same PtdIns(3,4)P2 pool. Pretreatment of plate-
lets with both the synthetic peptide RGDS in order to block 
(XnbP3 integrin/fibrinogen interaction [18] and calpeptin did 
not induce significantly additive effects on [32P]PtdIns(3,4)P2 
inhibition (Table 1). It should be noted that, as in the case of 
Glanzmann's thrombasthenic platelets lacking 0Cnbp3 integrin 
[18], we never obtained a total inhibition of [32P]PtdIns(3,4)P2 
in RGDS- and calpeptin-treated platelets upon thrombin 
stimulation. These data argue in favor of, at least, two inde-















Fig. 1. Effect of calpeptin treatment on thrombin-induced platelet aggregation and secretion. Washed platelets were pretreated in the absence 
or presence of calpeptin (50-100 ug/ml) or DMSO (vehicle; 0.3%) for 5 min and were stimulated by thrombin (1 NIH U/ml). [14C]Serotonin se-
cretion and aggregation were measured as described in Section 2. Platelet aggregation data are from one representative of three independent ex-
periments with similar results. Serotonin release data are means ± S.D. of four independent experiments and are represented below aggregation 
curves. 
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Fig. 2. Dose-dependent inhibition of PtdIns(3,4)P2 production in 
thrombin-stimulated platelets by calpeptin. Washed platelets were 
pretreated in the absence (THR) or presence of increased concentra-
tions of calpeptin (25-75 u,g/ml) or 0.3% DMSO for 5 min and 
were stimulated by thrombin (1 NIH U/ml). Lipids were extracted 
and separated as described in Section 2. The [32P]PtdIns(3,4)P2 level 
(from 9X108 platelets) is expressed in counts/min, and data are 
means ± S.E. from four independent experiments. Radioactivity of 
[32P]PtdIns(3,4)P2 was undetectable in samples of resting platelets 
and is not presented. Student's (-test (unpaired) gave probabilities 
of the observed means to be identical as indicated: *P<0.05, 
"P<0.01. 
thrombin-stimulated platelets. Only oinbp3 integrin-dependent 
pathway of PtdIns(3,4)P2 synthesis seems to be inhibited by 
calpeptin treatment. 
3.3. Translocation to the cytoskeleton of the p85 regulatory 
subunit of Ptdlns 3-kinase is not inhibited upon calpeptin 
treatment 
Our previous data have demonstrated that translocation of 
the p85 regulatory subunit of Ptdlns 3-kinase to the cytoskel-
eton was closely related to PtdIns(3,4)P2 synthesis in throm-
bin-stimulated platelets [14]. Since calpains have been in-
volved in cytoskeleton reorganization upon platelet 
stimulation, we asked for a possible modification of p85 local-
ization upon calpeptin treatment. As shown in Fig. 3, this was 
not the case since p85 translocation to the cytoskeleton was 
not impaired by calpeptin until 75 (ig/ml. 
Table 1 
Effect of tetrapeptide RGDS on calpeptin-induced inhibition of 
PtdIns(3,4)P2 synthesis 
Inhibitor Inhibition of PtdIns(3,4)P2 synthesis (%) 
Calpeptin 54 ± 14 
RGDS 73 ± 16 
Calpeptin+RGDS 83 ± 12 
Platelet preparation and activation by thrombin (1 NIH U/ml) were 
as described under Section 2. Calpeptin (75 |J.g/ml) and RGDS (100 
uM) were added to the platelet suspension 5 min and 15 s before 
thrombin, respectively. Results represent percentages of inhibition of 
[32P]PtdIns(3,4)P2 labeling compared to control values (platelets 
stimulated with thrombin in the absence of inhibitor). Values repre-
sent means ± S.D. (n = 4). 
Fig. 3. Effect of calpeptin on cytoskeletal relocalization of p85 upon 
thrombin stimulation. After processing as described in Section 2, cy-
toskeletal proteins from 3X108 platelets in resting state (R) or pre-
treated in the absence (THR) or presence of calpeptin (25-75 |J.g/ml) 
and stimulated by thrombin (1 NIH U/ml) were probed with anti-
p85. 
4. Discussion 
The aim of this study was to check for the possible involve-
ment of calpains in the regulation of anbP3 integrin-dependent 
Ptdlns 3-kinase activity in platelets. For this purpose, we used 
a cell permeant specific inhibitor of calpains, calpeptin, and 
followed 32P incorporation into the only Ptdlns 3-kinase 
product, PtdIns(3,4)P2, whose synthesis is partially controlled 
by anbp3 integrin engagement. 
In conditions where anbP3 integrin engagement was pre-
served (normal platelet secretion and aggregation), we ob-
served a dose-dependent inhibition of PtdIns(3,4)P2 synthesis 
upon calpeptin treatment. Interestingly, in these conditions, 
the maximal calpeptin inhibition value of PtdIns(3,4)P2 level 
(—60%) was close to that obtained with RGDS alone, which 
is a competitive inhibitor of fibrinogen/anbP3 integrin interac-
tion. Moreover, we did not observe additive inhibitory effects 
when platelets were pretreated with both inhibitors. These 
data indicate that calpains are involved in the regulation of 
anbP3 integrin-dependent PtdIns(3,4)P2 synthesis. 
Calpains selectively hydrolyse cytoskeletal proteins such as 
talin or filamin [11]. Since we have previously shown that the 
0CnbP3 integrin-dependent PtdIns(3,4)P2 synthesis was corre-
lated to the translocation of the p85 regulatory subunit to 
the cytoskeleton in thrombin-stimulated platelets [14], we 
checked for the localization of p85 upon calpeptin treatment. 
In conditions where calpeptin induced 60% inhibition of 
PtdIns(3,4)P2, p85 remained fully translocated to the cytoske-
leton. Thus, calpains could influence either the translocation 
of the pi 10 catalytic subunit of Ptdlns 3-kinase, or its regu-
lation, or the degradation of PtdIns(3,4)P2. 
The data presented here suggest that calpains could repre-
sent an early step in anbP3 integrin-mediated signal transduc-
tion that is necessary for PtdIns(3,4)P2 accumulation. In our 
conditions, platelet aggregation was not significantly modified 
when 60% of PtdIns(3,4)P2 production was inhibited. This 
result suggests that the PtdIns(3,4)P2 pool inhibited by cal-
peptin treatment could be not involved in the irreversible 
character of platelet aggregation as suggested for platelets 
stimulated with thrombin-receptor-activating peptide 
(TRAP) [12]. Alternatively, thrombin stimulation might trig-
ger additional signalling pathways making it possible to en-
compass Ptdlns 3-kinase inhibition, in contrast with TRAP-
induced platelet aggregation. On the other hand, calpain-de-
pendent PtdIns(3,4)P2 production could be involved in cal-
pain-dependent platelet vesiculation since the Saccharomyces 
cerevisiae protein VPS34 is a Ptdlns 3-kinase implicated in 
vacuole morphogenesis [19], and Glanzmann's thrombas-
26 
thenic platelets seem to be not able to vesiculate in response to 
thrombin [20]. More widely, our demonstration of Ptdlns 3-
kinase regulation by calpains could be of importance with 
regard to the involvement of calpains in differentiation and 
cell cycle regulation. 
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